Pfizer's hemophilia B gene therapy succeeds in late-stage study
Pfizer's investigational gene therapy for hemophilia B, fidanacogene elaparvovec, met the primary endpoint in a Phase 3 trial. The trial involved adults males with a moderately severe to severe form of the disease. Pfizer plans to disclose additional key data from the study at a scientific conference in early 2023.
Published 5 months ago
News Articles
More
Filters
Filters
Time & Location
Sources are mostly out of (0)